Physician profile
Robert Evans
NPI 1194936625
$10,919.39
in general payments reported to CMS, 2019-2025
34 companies · $2,490 in 2025
The $2,490 reported for 2025 was more than what 84% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $503 · 2020: $363 · 2021: $1,586 · 2022: $1,971 · 2023: $1,901 · 2024: $2,105 · 2025: $2,490.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,496.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,496.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,621.24 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $555.57 | 2019-2025 | Entyvio |
| Janssen Biotech, INC. | $538.21 | 2019-2024 | Stelara |
| Madrigal Pharmaceuticals | $529.49 | 2024-2025 | Rezdiffra, Resmetirom |
| Ardelyx, INC. | $423.98 | 2022-2025 | Ibsrela |
| Aimmune Therapeutics, INC. | $408.33 | 2024-2025 | Zenpep |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $343.04 | 2019-2025 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $325.48 | 2024-2025 | Voquezna |
| Qol Medical, LLC | $298.95 | 2023-2025 | Sucraid, Sucraid |
| Pfizer INC. | $221.37 | 2019-2024 | |
| Genzyme Corporation | $171.28 | 2022-2025 | |
| Ferring Pharmaceuticals INC. | $159.61 | 2019-2024 | Rebyota |
| Regeneron Healthcare Solutions, INC. | $139.77 | 2022-2024 | Dupixent |
| Lilly USA, LLC | $130.33 | 2024 | Omvoh |
| Shionogi INC | $123.17 | 2019-2020 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $107.08 | 2021-2025 | Sutab, Suflave |
| Celgene Corporation | $94.31 | 2021-2023 | Zeposia |
| Janssen Scientific Affairs, LLC | $88.24 | 2025 | Tremfya |
| Intercept Pharmaceuticals, INC. | $86.10 | 2020-2024 | Ocaliva |
| Ironwood Pharmaceuticals, INC | $76.21 | 2021-2022 | |
| Organon LLC | $70.71 | 2024-2025 | Hadlima |
| Nestle Healthcare Nutrition INC. | $69.73 | 2020-2022 | |
| Gilead Sciences, INC. | $67.04 | 2020-2025 | |
| Redhill Biopharma INC. | $56.38 | 2024-2025 | Talicia |
| Allergan, INC. | $41.33 | 2019 | |
| Endogastric Solutions, INC | $36.00 | 2022-2023 | Esophyx |
| Astrazeneca Pharmaceuticals Lp | $33.92 | 2023 | Andexxa |
| Novo Nordisk INC | $19.42 | 2025 | Wegovy |
| Merck Sharp & Dohme LLC | $16.31 | 2022 | |
| Mallinckrodt Hospital Products INC. | $15.10 | 2023 | Terlivaz |
| Medtronic, INC. | $14.01 | 2023 | Intellis Adaptivestim |
| Pentax of America, INC. | $13.67 | 2023 | Imagina |
| Daiichi Sankyo INC. | $12.68 | 2022 | |
| Dova Pharmaceuticals | $11.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.